A review of therapeutic inertia in hypertension highlights the gap between clinical trials and real-world practice, providing rationale for an ongoing trial of amlodipine/olmesartan medoxomil.
This article highlights the problem of therapeutic inertia in hypertension and provides the rationale for an ongoing study using fixed-dose amlodipine/olmesartan medoxomil to improve blood pressure control.
Uncontrolled blood pressure (BP) remains a leading contributor to cardiovascular disease and mortality worldwide. Although current practice guidelines recommend treating patients with hypertension to defined BP goals, the approach is not widely implemented, and BP control in clinical practice is much worse than that attained in clinical trials. Recent and ongoing clinical trials are utilizing more aggressive approaches with combination therapy as initial treatment. This article discusses the problem of therapeutic or clinical inertia when attempting to control hypertension and highlights differences in BP control rates between clinical trials and real-world practice. Additionally, the rationale for an ongoing treat-to-goal study using a fixed-dose combination of amlodipine/olmesartan medoxomil in patients with hypertension not controlled on monotherapy is provided.
Shawna D. Nesbitt (Fri,) conducted a review in Hypertension. Amlodipine/olmesartan medoxomil was evaluated. A review of therapeutic inertia in hypertension highlights the gap between clinical trials and real-world practice, providing rationale for an ongoing trial of amlodipine/olmesartan medoxomil.